Anterra Capital
Anterra Capital is a venture capital firm based in Amsterdam, Netherlands, founded in 2013. The firm specializes in investing in fast-growing companies that enhance the global food supply chain's safety, efficiency, and sustainability. Anterra Capital focuses on businesses that are commercializing innovative technologies and services across various segments of the food supply chain, including agro inputs, precision farming, logistics, and consumer safety. The firm typically invests in companies that are already generating revenue and have strong growth potential, targeting investments ranging from EUR 1M to EUR 15M. Anterra Capital takes significant minority equity positions and plays an active role on the boards of its portfolio companies. Additionally, the firm emphasizes long-term partnerships with management teams to foster lasting value and supports its portfolio companies in securing further capital from other professional investors.
Animol Discovery
Series C in 2024
Animol Discovery focuses on developing innovative veterinary medicines through its proprietary drug discovery technology. The company specializes in creating small molecule active pharmaceutical ingredients tailored for the unique needs of veterinary patients. Utilizing a technology platform built on DNA-encoded chemicals, Animol enables accelerated ultra-high throughput screening processes, allowing for the simultaneous evaluation of target and anti-target activities. This approach aims to streamline the discovery of effective treatments for pets, addressing a significant need in the animal health industry. Led by a team of experts with extensive experience in bringing veterinary drugs to market, Animol is committed to advancing the field of veterinary medicine.
Animol Discovery
Series B in 2023
Animol Discovery focuses on developing innovative veterinary medicines through its proprietary drug discovery technology. The company specializes in creating small molecule active pharmaceutical ingredients tailored for the unique needs of veterinary patients. Utilizing a technology platform built on DNA-encoded chemicals, Animol enables accelerated ultra-high throughput screening processes, allowing for the simultaneous evaluation of target and anti-target activities. This approach aims to streamline the discovery of effective treatments for pets, addressing a significant need in the animal health industry. Led by a team of experts with extensive experience in bringing veterinary drugs to market, Animol is committed to advancing the field of veterinary medicine.
Animol Discovery
Series B in 2022
Animol Discovery focuses on developing innovative veterinary medicines through its proprietary drug discovery technology. The company specializes in creating small molecule active pharmaceutical ingredients tailored for the unique needs of veterinary patients. Utilizing a technology platform built on DNA-encoded chemicals, Animol enables accelerated ultra-high throughput screening processes, allowing for the simultaneous evaluation of target and anti-target activities. This approach aims to streamline the discovery of effective treatments for pets, addressing a significant need in the animal health industry. Led by a team of experts with extensive experience in bringing veterinary drugs to market, Animol is committed to advancing the field of veterinary medicine.
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.
Animol Discovery
Series A in 2020
Animol Discovery focuses on developing innovative veterinary medicines through its proprietary drug discovery technology. The company specializes in creating small molecule active pharmaceutical ingredients tailored for the unique needs of veterinary patients. Utilizing a technology platform built on DNA-encoded chemicals, Animol enables accelerated ultra-high throughput screening processes, allowing for the simultaneous evaluation of target and anti-target activities. This approach aims to streamline the discovery of effective treatments for pets, addressing a significant need in the animal health industry. Led by a team of experts with extensive experience in bringing veterinary drugs to market, Animol is committed to advancing the field of veterinary medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.